GB947912A - Braxy and/or blackleg and/or black disease vaccines - Google Patents
Braxy and/or blackleg and/or black disease vaccinesInfo
- Publication number
- GB947912A GB947912A GB861959A GB861959A GB947912A GB 947912 A GB947912 A GB 947912A GB 861959 A GB861959 A GB 861959A GB 861959 A GB861959 A GB 861959A GB 947912 A GB947912 A GB 947912A
- Authority
- GB
- United Kingdom
- Prior art keywords
- cells
- vaccine
- medium
- toxin
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title abstract 9
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000002609 medium Substances 0.000 abstract 6
- 238000002360 preparation method Methods 0.000 abstract 6
- 239000003053 toxin Substances 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 231100000033 toxigenic Toxicity 0.000 abstract 4
- 230000001551 toxigenic effect Effects 0.000 abstract 4
- 231100000765 toxin Toxicity 0.000 abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 abstract 2
- 241001494479 Pecora Species 0.000 abstract 2
- 239000001963 growth medium Substances 0.000 abstract 2
- 239000006166 lysate Substances 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 239000011780 sodium chloride Substances 0.000 abstract 2
- 241000283690 Bos taurus Species 0.000 abstract 1
- 241000206044 Clostridium chauvoei Species 0.000 abstract 1
- 241000186581 Clostridium novyi Species 0.000 abstract 1
- 241000193466 Clostridium septicum Species 0.000 abstract 1
- 241000283903 Ovis aries Species 0.000 abstract 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 abstract 1
- 206010043376 Tetanus Diseases 0.000 abstract 1
- 239000002250 absorbent Substances 0.000 abstract 1
- 230000002745 absorbent Effects 0.000 abstract 1
- SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 abstract 1
- 230000000890 antigenic effect Effects 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 238000005119 centrifugation Methods 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 238000000502 dialysis Methods 0.000 abstract 1
- 230000002255 enzymatic effect Effects 0.000 abstract 1
- 238000005189 flocculation Methods 0.000 abstract 1
- 230000016615 flocculation Effects 0.000 abstract 1
- 239000004615 ingredient Substances 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 235000013372 meat Nutrition 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 238000002156 mixing Methods 0.000 abstract 1
- 235000015097 nutrients Nutrition 0.000 abstract 1
- 239000008363 phosphate buffer Substances 0.000 abstract 1
- 239000002244 precipitate Substances 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000001632 sodium acetate Substances 0.000 abstract 1
- 235000017281 sodium acetate Nutrition 0.000 abstract 1
- 238000000108 ultra-filtration Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- C—CHEMISTRY; METALLURGY
- C06—EXPLOSIVES; MATCHES
- C06B—EXPLOSIVES OR THERMIC COMPOSITIONS; MANUFACTURE THEREOF; USE OF SINGLE SUBSTANCES AS EXPLOSIVES
- C06B45/00—Compositions or products which are defined by structure or arrangement of component of product
- C06B45/04—Compositions or products which are defined by structure or arrangement of component of product comprising solid particles dispersed in solid solution or matrix not used for explosives where the matrix consists essentially of nitrated carbohydrates or a low molecular organic explosive
- C06B45/06—Compositions or products which are defined by structure or arrangement of component of product comprising solid particles dispersed in solid solution or matrix not used for explosives where the matrix consists essentially of nitrated carbohydrates or a low molecular organic explosive the solid solution or matrix containing an organic component
- C06B45/10—Compositions or products which are defined by structure or arrangement of component of product comprising solid particles dispersed in solid solution or matrix not used for explosives where the matrix consists essentially of nitrated carbohydrates or a low molecular organic explosive the solid solution or matrix containing an organic component the organic component containing a resin
- C06B45/105—The resin being a polymer bearing energetic groups or containing a soluble organic explosive
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/166—Catalysts not provided for in the groups C08G18/18 - C08G18/26
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/08—Processes
- C08G18/16—Catalysts
- C08G18/22—Catalysts containing metal compounds
- C08G18/222—Catalysts containing metal compounds metal compounds not provided for in groups C08G18/225 - C08G18/26
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/38—Low-molecular-weight compounds having heteroatoms other than oxygen
- C08G18/3819—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen
- C08G18/3823—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing -N-C=O groups
- C08G18/3825—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing -N-C=O groups containing amide groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/30—Low-molecular-weight compounds
- C08G18/38—Low-molecular-weight compounds having heteroatoms other than oxygen
- C08G18/3819—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen
- C08G18/384—Low-molecular-weight compounds having heteroatoms other than oxygen having nitrogen containing nitro groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
- C08G18/72—Polyisocyanates or polyisothiocyanates
- C08G18/77—Polyisocyanates or polyisothiocyanates having heteroatoms in addition to the isocyanate or isothiocyanate nitrogen and oxygen or sulfur
- C08G18/78—Nitrogen
- C08G18/7868—Nitrogen containing nitro groups
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/83—Chemically modified polymers
- C08G18/833—Chemically modified polymers by nitrogen containing compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Polymers & Plastics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
A vaccine active against at least one of the following, namely Braxy in sheep, Black disease and Blackleg in sheep or cattle comprises an aqueous preparation including at least one of the following namely (A) at least 2.5 total combining units per ml. of preparation of toxoided toxin from a toxigenic strain of Clostridium septicum; (B) at least 5.0 flocculation equivalents per ml. of preparation of toxoided a -toxin from a toxigenic strain of Clostridium oedematiens type B and (C) at least 106 per ml. of preparation of killed cells of a toxigenic strain of Clostridium chauvoei, which cells may be partially or wholly replaced by an extract thereof, the preparation containing p not more than 1.0 mg. total nitrogen or 1.0 mg. protein nitrogen per individual antigenic component of the vaccine. The vaccine is prepared by culturing separately a toxigenic strain of Cl. chauvoei, Cl. septicum or Cl. oedematiens type B in a culture medium therefor; separating the cells from the culture medium; where required, toxoiding the toxin in the medium and ultrafiltering the medium to remove some of the water and medium ingredients; where required, killing the separated cells and, where required, extracting the whole or part of said cells; followed, where required, by blending the products so obtained to form a vaccine as above. The blackleg vaccine is obtained by cultivating Cl. chauvoei in a nutrient medium containing enzymatic digest of meat at pH 7.6 to 7.8 at 37 DEG C. under anaerobic conditions for 48 hours. After centrifugation, the cells are killed by formalinisation (1%) for 7-10 days until sterile. The medium is filtered and treated with 1% formalin at pH 7.4 and 37 DEG C. for 5 to 6 days to form toxoid. It is purified by (a) ultrafiltration through a collodion or cellulose membrane until the volume of the medium is reduced 50 times; (b) dialysis of the concentrated toxoided toxin against sodium acetate/acetic acid solution for 2 to 3 days and redissolving the precipitate so formed in a phosphate buffer at pH 6.5. Both killed cells and the purified toxoided toxin may be separately absorbed on to a parenterally acceptable absorbent such as aluminium hydroxide gel and then mixed together to form a vaccine which may also contain isotonic sodium chloride and a preservative. The braxy vaccine consists of a toxoid and lysate of cells of Cl. septicum. The lysate being prepared by treating the cells with strong saline and dialysing to remove inorganic salts. Braxy, Blackleg and Black Disease vaccines may be mixed, either singly or in combination, with preparations active against tetanus and/or Pulpy Kidney Disease in lambs. Specification 901,433 is referred to.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB861959A GB947912A (en) | 1959-03-12 | 1959-03-12 | Braxy and/or blackleg and/or black disease vaccines |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB861959A GB947912A (en) | 1959-03-12 | 1959-03-12 | Braxy and/or blackleg and/or black disease vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB947912A true GB947912A (en) | 1964-01-29 |
Family
ID=9855963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB861959A Expired GB947912A (en) | 1959-03-12 | 1959-03-12 | Braxy and/or blackleg and/or black disease vaccines |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB947912A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4264588A (en) * | 1979-05-10 | 1981-04-28 | The Charles River Breeding Laboratories, Inc. | Vaccine for Clostridium perfringens type E enterotoxemia of rabbits |
| US4292307A (en) * | 1977-09-30 | 1981-09-29 | Zemlyakova Valentina P | Vaccine and method for prophylaxis and treatment of clostridioses of animals and poultry |
-
1959
- 1959-03-12 GB GB861959A patent/GB947912A/en not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4292307A (en) * | 1977-09-30 | 1981-09-29 | Zemlyakova Valentina P | Vaccine and method for prophylaxis and treatment of clostridioses of animals and poultry |
| US4264588A (en) * | 1979-05-10 | 1981-04-28 | The Charles River Breeding Laboratories, Inc. | Vaccine for Clostridium perfringens type E enterotoxemia of rabbits |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Barnes | The enzymes of lymphocytes and polymorphonuclear leucocytes | |
| Snell et al. | Growth factors for bacteria: III. Some nutritive requirements of Lactobacillus delbrucki | |
| JP4129544B2 (en) | Multi-component clostridial vaccine using saponin adjuvant | |
| Dubos et al. | The effect of a tissue enzyme upon pneumococci | |
| KAMEYAMA et al. | Purification and some properties of kappa toxin of Clostridium perfringens | |
| CN107875377B (en) | Preparation method of clostridium perfringens type E toxoid vaccine | |
| CN107201326A (en) | One plant of actinobacillus pleuropneumoniae and its application | |
| GB947912A (en) | Braxy and/or blackleg and/or black disease vaccines | |
| McEwen | B. paludis: A new species of pathogenic anaerobic bacterium | |
| CN106177935A (en) | A kind of ruminant clostridial disease tetrad inactivated vaccine and preparation method thereof | |
| JPS6211090A (en) | Toreponema hyodicenteriae bacterin and its method | |
| SU997599A3 (en) | Process for preparing heterovaccine for treating trichomonas syndrome | |
| Ellner | Fate of partially purified C14-labeled toxin of Clostridium perfringens | |
| CN105169380A (en) | Bivalent propolis inactivated vaccine for rabbit hemorrhagic disease and multocida pasteurellosis and preparation method of bivalent propolis inactivated vaccine | |
| Tidwell et al. | Use of membrane filter in blood cultures. | |
| Auclair et al. | Formic acid as a growth stimulant for Lactobacillus lactis in autoclaved milk | |
| GB2023420A (en) | Preparations containing antigen from pasteurella haemolytica | |
| Fisher | Experimental Staphylococcal Infection of the Subcutaneous Tissue of the Mouse: II. Promotion of the Infection with Staphylococcal Cells and Products | |
| CN118201633A (en) | Clostridium difficile vaccine and preparation method thereof | |
| US3288680A (en) | Stabilized clostridium perfringens beta-toxoid vaccine | |
| RU2109519C1 (en) | Method of preparing vaccine for necrobacteriosis control in animals | |
| Springer et al. | Protection of mice against lethal Staphylococcus infection by Escherichia coli O86 fractions | |
| Garg et al. | Cellular and humoral immune responses in sheep experimentally injected with killed and live Corynebacterium pseudotuberculosis | |
| RU2092187C1 (en) | Inactivated vaccine for salmonellosis control in sheep | |
| CN111467488B (en) | Water-soluble composite immunoadjuvant and application thereof |